July industry news: Ipsen partners with Exicure on SNA therapies for neurodegenerative disorders

Written by Neuro Central

July industry news

In July’s industry news round-up: Ipsen has partnered with Exicure to research, develop and commercialize SNA therapies for neurodegenerative disorders; significant improvement in survival and motor milestones in babies with Type 1 spinal muscular atrophy has been shown for Roche’s risdiplam; Posit Science has identified the first effective intervention to address cognitive deficits that can persist for years after a mTBI; ClearPoint Neuro and Blackrock Neurotech to develop an automated surgical solution for implanting Brain Computer Interfaces into patients; and Wave Life Sciences have initiated dosing in Phase Ib/IIa FOCUS-C9 clinical trial of WVE-004 in amyotrophic lateral sclerosis and frontotemporal dementia.  Take a look at July’s headlines below: Ipsen partners with Exicure on SNA therapies for neurodegenerative disorders  Evrysdi® (risdiplam)...

To view this content, please register now for access

It's completely free